The current invention concerns a method for determining the presence of a (pre)cancerous cell in a liquid cell sample, comprising the steps of: suspending and preserving a cell sample obtained from a subject in a sample vial comprising a liquid medium, said liquid medium comprises means for labeling cells or epitope(s) on or in said cells; obtaining data from said labelled liquid cell sample; and determining the presence of said (pre)cancerous cells based on said obtained data; characterized in that said data comprises morphological data and biomarker data. In a further aspect, the invention relates to a liquid medium for fixing, preserving and labeling cells in a cell sample and a sample vial specifically designed to be used in conjunction with the current method.

The present disclosure relates to methods of determining whether a subject has cancer. More particularly, the present disclosure relates to a method of determining whether a subject has cancer when a pathological assessment of cell morphology is negative for the cancer. More particularly, the present disclosure relates to a method of determining whether a morphologically normal cell is malignant. Identification of malignant cells, when a pathological assessment of cell morphology is negative for cancer, is based upon detecting the binding of an anti-telomerase antibody to clinically relevant cells.

The present invention relates to a pharmaceutical use of actinin-4 involved in the induction of cervical cancer and more specifically, characterizes actinin-4 as a marker protein capable of inducing cervical cancer, thereby providing the pharmaceutical use of actinin-4 that can be used in the diagnosis, prevention or treatment of cervical cancer.

This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.

The present application discloses anti-GPNMB antibodies and methods of using the same. The antibodies are selected to bind to an epitope located in a C-terminal fragment of the protein and are selected for specificity in immunohistochemical assays. The antibodies are useful in, for example, immunohistochemical methods of detecting GPNMB-positive cells in tumors.

The present invention is a device for high-throughput detection, screening and disease management of cervical disease. The device is comprised of a solid support featuring multiple well-separated areas, each accommodating a patient sample, leading to simultaneous evaluation of patient samples. The device enables cytological staining, cervical Pap staining, and immunochemical staining using antibodies or combination of antibodies which are capable of binding to biomarkers that are overexpressed in cancer including in cervical carcinoma and dysplasia, as compared to normal controls. The device can be used in either manual or automated mode, and applied to any biological fluid or cell suspension from any biological specimen in view of a variety of cell biology assays, and in view of detection and screening of cervical and other diseases.

The present invention relates to biomarkers for cancer diagnosis and uses thereof, and more particularly to a composition for diagnosing or predicting cancer prognosis, comprising an agent for measuring levels of at least two biomarkers selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin in blood, and a method of using the biomarker to provide information about the diagnosis or prognosis of cancer.

In the present invention, it was confirmed that the level of complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), histidine-rich glycoprotein (HRG), and/or osteopontin (OPN) in blood of lung and/or hepatic cancer patients has been found to have different patterns than that of normal individuals, and the combination of these markers has been shown to improve the diagnosis of various cancers, including lung or hepatic cancer. Accordingly, the biomarkers of the present invention can be useful in cancer diagnosis and prognosis.

The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.

Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.

The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.